223 related articles for article (PubMed ID: 24517398)
1. Persistence and selection of an expanded B-cell clone in the setting of rituximab therapy for Sjögren's syndrome.
Hershberg U; Meng W; Zhang B; Haff N; St Clair EW; Cohen PL; McNair PD; Li L; Levesque MC; Luning Prak ET
Arthritis Res Ther; 2014 Feb; 16(1):R51. PubMed ID: 24517398
[TBL] [Abstract][Full Text] [Related]
2. Persistence of immunoglobulin-producing cells in parotid salivary glands of patients with primary Sjögren's syndrome after B cell depletion therapy.
Hamza N; Bootsma H; Yuvaraj S; Spijkervet FK; Haacke EA; Pollard RP; Visser A; Vissink A; Kallenberg CG; Kroese FG; Bos NA
Ann Rheum Dis; 2012 Nov; 71(11):1881-7. PubMed ID: 22615459
[TBL] [Abstract][Full Text] [Related]
3. Sequential therapy with belimumab followed by rituximab in Sjögren's syndrome associated with B-cell lymphoproliferation and overexpression of BAFF: evidence for long-term efficacy.
De Vita S; Quartuccio L; Salvin S; Picco L; Scott CA; Rupolo M; Fabris M
Clin Exp Rheumatol; 2014; 32(4):490-4. PubMed ID: 24802131
[TBL] [Abstract][Full Text] [Related]
4. Proteogenomic analysis of the autoreactive B cell repertoire in blood and tissues of patients with Sjögren's syndrome.
Broeren MGA; Wang JJ; Balzaretti G; Groenen PJTA; van Schaik BDC; Chataway T; Kaffa C; Bervoets S; Hebeda KM; Bounova G; Pruijn GJM; Gordon TP; De Vries N; Thurlings RM
Ann Rheum Dis; 2022 May; 81(5):644-652. PubMed ID: 35144926
[TBL] [Abstract][Full Text] [Related]
5. Rituximab therapy in primary Sjögren's syndrome.
Alcântara C; Gomes MJ; Ferreira C
Ann N Y Acad Sci; 2009 Sep; 1173():701-5. PubMed ID: 19758218
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment of a patient with primary Sjögren's syndrome with Rituximab.
Ring T; Kallenbach M; Praetorius J; Nielsen S; Melgaard B
Clin Rheumatol; 2006 Nov; 25(6):891-4. PubMed ID: 16283417
[TBL] [Abstract][Full Text] [Related]
7. Rituximab therapy for primary Sjögren's syndrome: an open-label clinical trial and mechanistic analysis.
St Clair EW; Levesque MC; Prak ET; Vivino FB; Alappatt CJ; Spychala ME; Wedgwood J; McNamara J; Moser Sivils KL; Fisher L; Cohen P;
Arthritis Rheum; 2013 Apr; 65(4):1097-106. PubMed ID: 23334994
[TBL] [Abstract][Full Text] [Related]
8. First report of improvement of coeliac disease in a patient with Sjögren's syndrome treated with rituximab.
Nikiphorou E; Hall FC
Rheumatology (Oxford); 2014 Oct; 53(10):1906-7. PubMed ID: 24729401
[No Abstract] [Full Text] [Related]
9. Treatment approaches in primary Sjogren syndrome.
Vissink A; Kallenberg CG; Bootsma H
JAMA; 2010 Nov; 304(18):2015-6; author reply 2016. PubMed ID: 21063008
[No Abstract] [Full Text] [Related]
10. [B-cell depletion and primary Sjögren's syndrome: is there a role for rituximab?].
Atzeni F; Sarzi-Puttini P
Reumatismo; 2010; 62(2):87-8. PubMed ID: 20657883
[No Abstract] [Full Text] [Related]
11. B cell reconstitution and T helper cell balance after rituximab treatment of active primary Sjögren's syndrome: a double-blind, placebo-controlled study.
Abdulahad WH; Meijer JM; Kroese FG; Meiners PM; Vissink A; Spijkervet FK; Kallenberg CG; Bootsma H
Arthritis Rheum; 2011 Apr; 63(4):1116-23. PubMed ID: 21225693
[No Abstract] [Full Text] [Related]
12. Complete remission of protein-losing gastroenteropathy associated with Sjögren's syndrome by B cell-targeted therapy with rituximab.
Uraoka Y; Tanigawa T; Watanabe K; Machida H; Okazaki H; Yamagami H; Watanabe K; Tominaga K; Watanabe T; Fujiwara Y; Arakawa T
Am J Gastroenterol; 2012 Aug; 107(8):1266-8. PubMed ID: 22859008
[No Abstract] [Full Text] [Related]
13. Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study.
Carubbi F; Cipriani P; Marrelli A; Benedetto P; Ruscitti P; Berardicurti O; Pantano I; Liakouli V; Alvaro S; Alunno A; Manzo A; Ciccia F; Gerli R; Triolo G; Giacomelli R
Arthritis Res Ther; 2013 Oct; 15(5):R172. PubMed ID: 24286296
[TBL] [Abstract][Full Text] [Related]
14. De novo oligoclonal expansions of circulating plasmablasts in active and relapsing IgG4-related disease.
Mattoo H; Mahajan VS; Della-Torre E; Sekigami Y; Carruthers M; Wallace ZS; Deshpande V; Stone JH; Pillai S
J Allergy Clin Immunol; 2014 Sep; 134(3):679-87. PubMed ID: 24815737
[TBL] [Abstract][Full Text] [Related]
15. [Efficiency of rituximab in an unusual form of primary Sjögren's syndrome: a case report].
Mrabet D; Meddeb N; Sahli H; Saadi F; Chéour E; Elleuch M; Sellami S
Therapie; 2010; 65(6):581-3. PubMed ID: 23189757
[No Abstract] [Full Text] [Related]
16. Anti-CD20 antibody in primary Sjögren's syndrome management.
Chen S; Liu Y; Shi G
Curr Pharm Biotechnol; 2014; 15(6):535-41. PubMed ID: 25213362
[TBL] [Abstract][Full Text] [Related]
17. Clonal salivary gland infiltrates associated with myoepithelial sialadenitis (Sjögren's syndrome) begin as nonmalignant antigen-selected expansions.
Bahler DW; Swerdlow SH
Blood; 1998 Mar; 91(6):1864-72. PubMed ID: 9490668
[TBL] [Abstract][Full Text] [Related]
18. Accumulation of Antigen-Driven Lymphoproliferations in Complement Receptor 2/CD21
Glauzy S; Boccitto M; Bannock JM; Delmotte FR; Saadoun D; Cacoub P; Ice JA; Sivils KL; James JA; Wolin SL; Meffre E
Arthritis Rheumatol; 2018 Feb; 70(2):298-307. PubMed ID: 29073352
[TBL] [Abstract][Full Text] [Related]
19. Maintenance of rituximab treatment in a patient with primary Sjögren's syndrome.
Lehner GF; Brunner-Palka M; Rettenbacher T; Schmidauer R; Herold M
Rheumatology (Oxford); 2014 Jul; 53(7):1349-50. PubMed ID: 24446469
[No Abstract] [Full Text] [Related]
20. Rituximab in central nervous system manifestations of patients with primary Sjögren's syndrome: results from the AIR registry.
Mekinian A; Ravaud P; Larroche C; Hachulla E; Gombert B; Blanchard-Delaunay C; Cantagrel A; Fain O; Sibilia J; Gottenberg JE; Mariette X;
Clin Exp Rheumatol; 2012; 30(2):208-12. PubMed ID: 22341206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
